<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04175691</url>
  </required_header>
  <id_info>
    <org_study_id>AISRNA</org_study_id>
    <nct_id>NCT04175691</nct_id>
  </id_info>
  <brief_title>Circulating Non-coding RNA in Acute Ischemic Stroke (AISRNA)</brief_title>
  <acronym>AISRNA</acronym>
  <official_title>Clinical Significance of Circulating Non-coding RNA in Acute Ischemic Stroke (AISRNA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing First Hospital, Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AISRNA is to analyze the expression pattern of circular RNA (circRNA), micro-RNA (miRNA) and
      long non-coding RNA (lncRNA) by next-generation sequencing in patients with acute ischemic
      stroke and healthy control. The candidate circRNA/miRNA/lncRNA will be verified as biomarkers
      for the detection and prognosis of acute ischemic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Noncoding RNAs have been highlighted to be involved in the pathological process of ischemic
      stroke (IS). The purpose of this protocol will investigate the expression pattern of circular
      RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA) by next-generation
      sequencing in patients with acute ischemic stroke and healthy control. The candidate
      circRNA/miRNA/lncRNA will be verified as biomarkers for the detection and prognosis of acute
      ischemic stroke. Distinctive expression patterns of circRNA/miRNA/lncRNA will be identified
      by the next-generation sequencing and individual quantitative real time polymerase chain
      reaction (qRT-PCR). A diagnostic or predictive model will be established using logistic
      regression. The panel of these altered ncRNAs may be associated with acute IS and could serve
      as a novel diagnostic or predictive method.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>90 Days</target_duration>
  <primary_outcome>
    <measure>Differential expression pattern of circRNA/miRNA/lncRNA</measure>
    <time_frame>90 days</time_frame>
    <description>Differential expression pattern of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA) will be compared between AIS group and HC group, thus candidate circRNA/miRNA/lncRNA will be verified as biomarkers for the detection and prognosis of AIS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of circRNA/miRNA/lncRNA in acute ischemic stroke</measure>
    <time_frame>90 days</time_frame>
    <description>The prognosis of AIS patients will be analyzed between differential expressed candidate miRNA/lncRNA after they have completed the systematic therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of circRNA/miRNA/lncRNA and inflammatory factors in acute ischemic stroke</measure>
    <time_frame>7 days</time_frame>
    <description>Correlation of circRNA/miRNA/lncRNA and inflammatory factors on admission will be explored in acute ischemic stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of circRNA/miRNA/lncRNA and stroke-associated infection</measure>
    <time_frame>30 days</time_frame>
    <description>Correlation of circRNA/miRNA/lncRNA and stroke-associated infection will be explored in acute ischemic stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic changes of circRNA/miRNA/lncRNA during the follow-up period</measure>
    <time_frame>90 days</time_frame>
    <description>Dynamic changes of circRNA/miRNA/lncRNA will be explored before and after endovascular therapy</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute Stroke</condition>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>AIS group</arm_group_label>
    <description>This group includes patients with acute ischemic stroke (AIS).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HC group</arm_group_label>
    <description>This group includes healthy controls (HC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Sequencing of circRNA/miRNA/lncRNA</intervention_name>
    <description>Next generation sequencing of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA)</description>
    <arm_group_label>AIS group</arm_group_label>
    <arm_group_label>HC group</arm_group_label>
    <other_name>Quantitative Real-time polymerase chain reaction</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      An 10 ml peripheral venous blood will be collected from the participants before and after
      interventions (i.e. intravenous thrombolysis and/or endovascular therapy)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        There will be 5 AIS patients and 5 HCs, whose data will be applied for construction of
        diagnostic and predictive models of circRNA/miRNA/lncRNA from the circulating blood. There
        will be 100 patients suspected of AIS (such as transient ischemic attack) 300 AIS patients,
        whose data will be applied for validation of such diagnosis and predictive models,
        respectively.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 years or older

          -  Confirmed acute ischemic stroke by a diffusion-weighted imaging-position lesion on
             magnetic resonance imaging (MRI) and a new lesion on a brain computed tomography (CT)
             scan

          -  Within 72 hours of symptom onset

          -  Good performance status

          -  Signed an approved informed consents

        Exclusion Criteria:

        -a history of hemorrhagic infarction, chronic kidney/liver diseases, peripheral arterial
        occlusive disease, active malignant disease, and inflammatory or infectious diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junshan Zhou, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junshan Zhou, M.D.</last_name>
    <phone>+8602587726218</phone>
    <email>zhjsh333@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qiwen Deng, M.D.</last_name>
    <phone>+8602587726218</phone>
    <email>qiw_deng@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanjing First Hospital, Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junshan Zhou, M.D.</last_name>
      <phone>+86025-87726218</phone>
      <email>zhjsh333@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Qiwen Deng, M.D.</last_name>
      <phone>+86025-87726218</phone>
      <email>qiw_deng@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://pubmed.ncbi.nlm.nih.gov/29997237/</url>
    <description>Differential Long Noncoding RNA Expressions in Peripheral Blood Mononuclear Cells for Detection of Acute Ischemic Stroke</description>
  </link>
  <results_reference>
    <citation>Deng QW, Li S, Wang H, Sun HL, Zuo L, Gu ZT, Lu G, Sun CZ, Zhang HQ, Yan FL. Differential long noncoding RNA expressions in peripheral blood mononuclear cells for detection of acute ischemic stroke. Clin Sci (Lond). 2018 Jul 31;132(14):1597-1614. doi: 10.1042/CS20180411. Print 2018 Jul 31.</citation>
    <PMID>29997237</PMID>
  </results_reference>
  <results_reference>
    <citation>Li S, Lu G, Wang D, He JL, Zuo L, Wang H, Gu ZT, Zhou JS, Yan FL, Deng QW. MicroRNA-4443 regulates monocyte activation by targeting tumor necrosis factor receptor associated factor 4 in stroke-induced immunosuppression. Eur J Neurol. 2020 Apr 26. doi: 10.1111/ene.14282. [Epub ahead of print]</citation>
    <PMID>32337817</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 21, 2019</study_first_submitted>
  <study_first_submitted_qc>November 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute ischemic stroke</keyword>
  <keyword>noncoding RNA</keyword>
  <keyword>clinical significance</keyword>
  <keyword>outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All information will be available to all researchers.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>All information will be available to all researchers when related investigation has been accepted publicly, and will be available for 5 years.</ipd_time_frame>
    <ipd_access_criteria>All information will be available to all researchers when related investigation has been accepted publicly.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

